4SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA received
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
As member of OCEAN Alliance, COSCO SHIPPING is dedicated to promoting the prosperity of global trade by enhancing our sc…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
HONICO solutions BatchMan and Easy Workload Scheduler part of EMA Radar™ Enterprise Management Associates (EMA), a l…
Cyntegrity, a front-runner in AI-augmented clinical trial risk management solutions, proudly announces its upcoming virt…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survi…